Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach.

The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Dapagliflozin alongside moderate calorie restricted diet leads to much higher rates of remission from early type 2 diabetes, a study found.

(Balcinrenone + dapagliflozin) is under clinical development by AstraZeneca and currently in Phase II for Proteinuria. According to GlobalData, Phase II drugs for Proteinuria have a 40% phase ...

Treatment concerns up to 150,000 patients in England with chronic heart failure Treatment concerns up to 150,000 patients in England with chronic heart failure The National Institute for Health and ...

NICE has recommended the extension of dapagliflozin as a treatment option for symptomatic chronic heart failure in patients with preserved or mildly reduced ejection fraction. In final draft ...